ClinicalTrials.gg
CompletedNCT06273592ERECTION 2Updated Nov 3, 2026

The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.

An interventional study of Animal-based meal and Plant-based meat meal in Erectile Dysfunction, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to male participants aged 18 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Prevention

Updated Nov 3, 2026Now CompletedNow Active, not recruiting+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 32 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.

Enrollment
113th of 164
30 · median 75
Started
2024
with 9 others
No phase
62 of 180
16 open now
Registered
163rd of 180
by date

Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 113th largest by enrollment of the 164 interventional ones that give a count, is one of 10 that started in 2024, is one of 62 with no phase, and was the 163rd registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 32 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Erectile Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to determine whether erectile function is differentially impacted by a single plant-based meat meal versus a single animal meat meal in healthy men with normal erectile function.

Read the detailed description

Visit 1 (Screening Visit):

After reviewing and signing consent, subjects will be screened for the study. Screening will consist of the following:

  • Complete IIEF
  • Record medical history, concomitant medications
  • Measure height and weight, calculate BMI
  • Vitals
  • A one-time blood draw of \~ 10 ml of blood will be performed during the screening visit for total testosterone, sex hormone binding globulin and Thyroid Stimulating Hormone.
  • Query subject regarding the presence of genital rash or lesions. Subjects will be asked, "do you have a rash or lesion on your penis or surrounding area?"

If the IIEF score is abnormal, subjects will be advised to contact their primary care provider.

If the STOP-BANG score identified intermediate or high risk for OSA, subjects will be advised to contact their primary care provider.

If the subject has insomnia, the subject will be given the recommendation to contact their primary care provider.

Each subject will be contacted by phone with their blood results. If abnormal, subject will be given the recommendation to contact their primary care provider.

If the subject has no primary care provider, contact information for primary care will be given.

Subjects meeting inclusion and exclusion criteria will be randomized into the study, into either sequence one or sequence two. Once enrolled, subjects will be asked to not modify their dietary habits throughout the duration of the study other than during the two evenings when food is provided (see below).

Sequence One:

Visit 2:

Subjects will return to the study center. Subjects will be asked not to use mouthwash and/or other breath fresheners that day. Anthropomorphic and blood pressure and heart rate recordings will be made.

Subjects will be taught how to use the Rigiscan™ device. Subjects will receive one plant-based dinner (food will be provided by Montefiore-Einstein Food Services.) Subjects will then leave the study center and will consume their usual diet until 4pm EST. Water will be the only beverage allowed after 4pm. Dinner should be consumed at 8:30pm, EST. That night, subjects will do a Rigiscan™ assessment overnight at their home. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. After consuming the dinner, subject will only drink/consume water until the end of Rigiscan recording (at least 7 hours).

Visit 3:

Subjects will return to the study center the day after the Rigiscan™ assessment and bring the Rigiscan™ device with them. Anthropomorphic and blood pressure and heart rate recordings will be made.

There will then be a washout period for 5-8 days and subjects will be instructed to return to their usual dietary habits during this washout period.

Visit 4:

After the washout period, subjects will return to the study center. Subjects will have been asked not to use mouthwash and/or other breath fresheners that day. Anthropomorphic and blood pressure and heart rate recordings will be taken.

Subjects will receive one animal-based dinner (food will be provided by Montefiore-Einstein Food Services.) Subjects will then leave the study center and they will consume their usual diet until 4pm EST. Water will be the only beverage consumed after 4pm. Dinner should be consumed at 8:30pm, EST. That night, subjects will do a Rigiscan™ assessment overnight at their home. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. After consuming the dinner, subject will only drink/consume water until the end of Rigiscan recording (at least 7 hours).

Visit 5 (End of Study):

Subjects will return to the study center the day after the Rigiscan™ assessment and bring the Rigiscan™ device with them. Anthropomorphic and blood pressure and heart rate recordings will be made.

Sequence Two is identical to Sequence One, except that the order of the plant-based and animal-based meals is reversed.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Diet
  • Erectile function
  • Plant-based
  • Animal-based
04

Who can participate

Ages eligible
18 Years to 32 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject provides written and HIPAA authorization in English before any study procedures are conducted. (If the subject is a fluent Spanish and/or other language speaker, subject must also be fluent in English (understanding and speaking) to be eligible for this study.)
  • IIEF score greater or equal to 22
  • Subject is currently taking no medication other than prn MDIs No change in supplements if applicable
  • Subject will have had penile sexual intercourse (either vaginal or anal penetration) within 12 weeks of enrollment
  • Male (biological) aged 18-32 years old
  • Lives within commuting distance of Montefiore Health System
  • Subject's significant other (if applicable) agrees to support the subject during the study
  • Subject agrees to avoid all illicit drugs, NSAIDS, and alcohol for at least two days prior to Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  • Subject agrees to refrain from sexual activity for at least 24 hours prior to Rigiscan™ placement and to have no sexual activity on the days and nights of Rigiscan™ recording
  • Subject agrees to not view, read, or otherwise consume erotic or pornographic material for at least 24 hours prior to the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  • Subject agrees to not have an orgasm for 24 hours prior to both the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  • Subject agrees to come to Montefiore to undergo Rigiscan™ training
  • Subject agrees to only consume/drink permitted food/beverages
  • Subject agrees to attend all in person visits at Montefiore and to undergo all blood draws and other testing
  • Subject agrees to not use mouthwash or mouth rinses or intentionally spit for the entire duration of the study. Subjects will be asked to refrain from using mouthwash for at least 2 days prior to enrollment. Subject agrees to not brush his teeth and to not use toothpaste for 24 hours preceding Rigiscan testing. Tooth brushing is otherwise permissible.
  • \<28.5, BMI >=18.5, weight >110 lbs
  • Subject agrees to comply with the study procedures and visits
  • Subject exercises for at least 15 minutes at least two times per week
  • If exercise is done, subjects will exercise for the same amount of time and at a similar intensity each day of Rigiscan™ testing. Otherwise, no exercise will be performed on Rigiscan™ days.
  • If enrolled, subjects agree to not modify their dietary habits throughout the duration of the study other than during the two evenings when food is provided.
  • If enrolled, subjects agree to fast when requested to fast

Exclusion criteria

Exclusion Criteria:

  • Relevant dietary allergy
  • Vegetarian or Vegan dietary pattern
  • History of an eating disorder and/or food addiction
  • Hypertension and or history of hypertension with or without medical treatment. Systolic blood pressure > 150mmHg and/or diastolic blood pressure >100mmHg on Visit one. Heart rate >99 on Visit one. Systolic blood pressure \< 85mmHg and/or diastolic blood pressure \< 50mmHg on Visit one. Heart rate \< 35 on Visit one
  • >=28.5, BMI \<18.5, or weight \<= 110lbs
  • Known chronic medical disease other than non-inflammatory musculoskeletal disease, asthma
  • Subjects who are taking benzodiazepines, stimulants (e.g. for ADHD), SSRI, anti-depressants and/or beta blockers
  • Obstructive sleep apnea (OSA) diagnosis or an ongoing evaluation for possible OSA
  • Score greater than 2 on the STOP-Bang OSA screening tool
  • Having the diagnosis of Restless Leg Syndrome
  • Having insomnia as defined by: Subject with insomnia would have difficulty initiating or maintaining sleep (30 minutes or more at sleep initiation or 30 minutes or more to fall back asleep if wakes during the night). The above occurs at least 3 times per week for at least 1 month. Furthermore, there must be adequate opportunity for sleep and there must be associated morbidity (feels tired during the day). Definition based on: The International Classification of Sleep Disorders - Third Edition (ICSD-3), 2014
  • History of kidney disease or hyperkalemia
  • Subject has received an drug within 30 days prior to signing consent
  • Erectile dysfunction
  • Has any condition (e.g., psychiatric illness) or situation that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's ability to adhere with study procedures
  • Currently undergoing treatment for Peyronie's Disease
  • Abnormal Testosterone or Thyroid Stimulating Hormone level
  • Treated hypogonadism or hypothyroidism
  • Planned travel during the study
  • History of substance abuse in the last 12 months
  • Illicit drug use, smoking, or vaping within 4 weeks
  • Upper respiratory illness within two weeks on screening
  • If profession requires being on call, no overnight or on call duties during the study
  • Subject reports any communicable skin or venereal disease
  • Transgender status (Individuals who have undergone or are undergoing hormone replacement therapy or who have undergone gender affirming surgery. Individuals who plan to begin hormone replacement therapy or to undergo gender affirming surgery during the study.)
  • positive status via direct medical history
  • Subject reports rash or lesion on the penis or surrounding area
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Plant-based

    The plant-based arm consists of consuming one plant-based meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections. The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat.

    Other: Plant-based meat meal

  • Active comparator
    Animal-based

    The animal-based arm consists of consuming one animal meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections. The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat.

    Other: Animal-based meal

Interventions

  • OtherAnimal-based meal

    Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.

    Also known as: Animal-based meal will be provided by Montefiore-Einstein Food Services

  • OtherPlant-based meat meal

    Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.

    Also known as: A Beyond Meat product will be used as the plant-based meat and will be provided by Montefiore-Einstein Food Services

06

What researchers measure

Primary outcomes

  1. Percent of time ≥50% erect during overnight Rigiscan™ use after 1 meal

    The first 5 minutes of Rigiscan™ recording is discarded. Erection time is the total time (in minutes) when penile rigidity is ≥ 50% at both the tip and base of the penis with a concurrent increase in penile tumescence at both the tip and base of the penis compared to baseline tumescence as measured by Rigiscan™ during overnight Rigiscan™ use, divided by the total time (in minutes) of overnight Rigiscan™ use. Overnight Rigiscan™ use time is defined as starting 5 minutes after the start of the Rigiscan™ recording and the end of Rigiscan™ use is defined as the last time the tip or base was \>=10% rigid with a corresponding concurrent increase in penile tumescence at the tip or base compared to baseline tumescence. This total time window from start to end is the Rigiscan™ use time

    Time frame: During overnight sleep directly after consuming 1 meal

Secondary outcomes

  1. Percent of time ≥60% erect during overnight Rigiscan™ use after 1 meal

    The first 5 minutes of Rigiscan™ recording is discarded. Erection time is the total time (in minutes) when penile rigidity is ≥ 60% at both the tip and base of the penis with a concurrent increase in penile tumescence at both the tip and base of the penis compared to baseline tumescence as measured by Rigiscan™ during overnight Rigiscan™ use, divided by the total time (in minutes) of overnight Rigiscan™ use. Overnight Rigiscan™ use time is defined as starting 5 minutes after the start of the Rigiscan™ recording and the end of Rigiscan™ use is defined as the last time the tip or base was \>=10% rigid with a corresponding concurrent increase in penile tumescence at the tip or base compared to baseline tumescence. This total time window from start to end is the Rigiscan™ use time.

    Time frame: During overnight sleep directly after consuming 1 meal

  2. Percent of time ≥60% erect at base of the penis during overnight Rigiscan™ use after 1 meal

    The first 5 minutes of Rigiscan™ recording is discarded. Erection time is the total time (in minutes) when penile base rigidity is ≥ 60% with a concurrent increase in penile tumescence at the base of the penis compared to baseline tumescence as measured by Rigiscan™ during overnight Rigiscan™ use, divided by the total time (in minutes) of overnight Rigiscan™ use. Overnight Rigiscan™ use time is defined as starting 5 minutes after the start of the Rigiscan™ recording and the end of Rigiscan™ use is defined as the last time the tip or base was \>=10% rigid with a corresponding concurrent increase in penile tumescence at the tip or base compared to baseline tumescence. This total time window from start to end is the Rigiscan™ use time.

    Time frame: During overnight sleep directly after consuming 1 meal

Other outcomes

  1. Heart rate

    Comparing heart rate by dietary pattern at both time points after overnight sleep after consuming the 1 meal and compared to its respective baseline in beats/minute.

    Time frame: Pre and post overnight Rigiscan recording. Up to 7 months.

  2. Blood pressure

    Comparing blood pressure (both systolic and diastolic) by dietary pattern at both time points after overnight sleep after consuming the 1 meal and compared to its respective baseline in mmHg.

    Time frame: Pre and post overnight Rigiscan recording. Up to 7 months.

  3. Percent of time ≥10% erect during overnight Rigiscan™ use after 1 meal.

    The first 5 minutes of Rigiscan™ recording is discarded. Erection time is the total time (in minutes) when penile rigidity is ≥ 10% at both the tip and base of the penis with a concurrent increase in penile tumescence at both the tip and base of the penis compared to baseline tumescence as measured by Rigiscan™ during overnight Rigiscan™ use, divided by the total time (in minutes) of overnight Rigiscan™ use. Overnight Rigiscan™ use time is defined as starting 5 minutes after the start of the Rigiscan™ recording and the end of Rigiscan™ use is defined as the last time the tip or base was \>=10% rigid with a corresponding concurrent increase in penile tumescence at the tip or base compared to baseline tumescence. This total time window from start to end is the Rigiscan™ use time.

    Time frame: During overnight sleep directly after consuming 1 meal.

07

Study locations

1 site
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2026, 25 months.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 25 months is below that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2027 → Oct 2026, last on Nov 3, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jun 2027 → Oct 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 22, 2024
StartActual
Sep 19, 2024
Primary completionActual
Oct 28, 2026was Jun 2027
CompletionActual
Oct 28, 2026was Jun 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 6, 2026 · changed Nov 3, 2026
Primary completion
Jun 2027→Oct 28, 2026 (actual)
moved 2 times, Oct 6, 2026 – Nov 3, 2026
Study completion
Jun 2027→Oct 28, 2026 (actual)
moved 2 times, Oct 6, 2026 – Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercent of time with ≥7050% erectionerect during overnight sleepRigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months. → During overnight sleep directly after consuming 1 meal
Oct 6, 2026
Secondary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedPercent of time ≥60% erect during overnight Rigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming 1 meal
  • AddedPercent of time ≥60% erect at base of the penis during overnight Rigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming 1 meal
  • RemovedErection events per hour during overnight sleep after 1 mealTime frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months.
  • RemovedTumescence events per hour during overnight sleep after 1 meal.Time frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months.
  • Addedother outcomePercent of time ≥10% erect during overnight Rigiscan™ use after 1 meal.Time frame: During overnight sleep directly after consuming 1 meal.
Oct 6, 2026
Show all 2 updates
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Primary completion Oct 20, 2026→Oct 28, 2026 (now actual)
    Study completion Oct 20, 2026→Oct 28, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2027→Oct 20, 2026
    Study completion Jun 2027→Oct 20, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent of time with ≥7050% erectionerect during overnight sleepRigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months. → During overnight sleep directly after consuming 1 meal
    Secondary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedPercent of time ≥60% erect during overnight Rigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming 1 meal
    • AddedPercent of time ≥60% erect at base of the penis during overnight Rigiscan™ use after 1 mealTime frame: During overnight sleep directly after consuming 1 meal
    • RemovedErection events per hour during overnight sleep after 1 mealTime frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months.
    • RemovedTumescence events per hour during overnight sleep after 1 meal.Time frame: During overnight sleep directly after consuming the 1 meal. Up to 7 months.
    • Addedother outcomePercent of time ≥10% erect during overnight Rigiscan™ use after 1 meal.Time frame: During overnight sleep directly after consuming 1 meal.
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06273592
Collaborators
Beyond Meat, San Diego Sexual Medicine
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Sep 19, 2024
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 3, 2026

Study contacts

Robert Ostfeld, MD, MSc
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion